537049-05-1

Basic information

• Product Name: Carbamic acid, [3-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]phenyl]-, 1,1-dimethylethyl ester
• CAS NO: 537049-05-1
• Molecular Formula: C14H15Cl2N5O2
• Molecular Weight: 356.211
• Mol File: 537049-05-1.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Carbamic acid, [3-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]phenyl]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [3-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]phenyl]-, 1,1-dimethylethyl ester(537049-05-1)
• EPA Substance Registry System: Carbamic acid, [3-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]phenyl]-, 1,1-dimethylethyl ester(537049-05-1)

Safety Data

• Hazardous Substances Data: 537049-05-1(Hazardous Substances Data)

Upstream product

• 108-77-0 1,3,5-trichloro-2,4,6-triazine 
• 68621-88-5 (3-aminophenyl)carbamic acid tert-butyl ester 

Downstream Products

• 878203-39-5 2-(2-[4-aminophenyl]ethylamino)-4-(3-N-tert-butoxycarbonylamino)phenylamino-6-chloro-1,3,5-triazine 
• 1192801-06-1 2-[4-([3-tert-butoxycarbonylaminophenyl]amino)-6-chloro[1,3,5]-triazine-2-ylamino]ethanol 
• 1192801-08-3 2-[4-([3-tert-butoxycarobnylaminophenyl]amino)-6-[2-[4-[4-([3-tert-butoxycarbonylaminophenyl]amino)-6-chloro[1,3,5]triazine-2-ylamino]phenyl]ethylamino][1,3,5]triazine-2-ylamino]ethanol 
• 878203-48-6 2-(3-[N-tert-butoxycarbonylaminophenyl]amino)-4-chloro-6-cyclopentylamino-1,3,5-triazine 
• 537049-10-8 {3-[4-(3-{4-[3-(4,6-dichloro-[1,3,5]triazin-2-ylamino)-phenylamino]-6-pentylamino-[1,3,5]triazin-2-ylamino}-phenylamino)-6-pentylamino-[1,3,5]triazin-2-ylamino]-phenyl}-carbamic acid tert-butyl ester 
• 537049-09-5 C₄₇H₅₈N₁₄O₄ 
• 537049-08-4 C₄₂H₄₆ClN₁₃O₄ 
• 537049-07-3 C₃₃H₄₀N₈O₄ 
• 537049-06-2 C₂₈H₂₈ClN₇O₄ 

Relevant articles and documents

USE OF HIGH AFFINITY MONOCLONAL ANTIBODY PRODUCT BINDERS TO INCREASE THE DURATION OF ACTION OF THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS IN A BIOLOGIC TISSUE

An anchor molecule is provided that (1) binds monoclonal antibody products with high affinity and (2) is anchored in a biologic tissue of interest. Therapeutic antibodies can either be delivered to the biologic tissue before, during, or after the delivery of the anchor molecule. Because the present invention binds monoclonal antibody products and is anchored in a biologic tissue, the result is that monoclonal antibody products are also anchored in a biologic tissue.

An efficient kilogram-scale synthesis of N,N2 -bis(4,6-disubstituted 1,3,5-triazin-2-yl)-4-aminophenetylamine

A practical large-scale synthesis was developed for the preparation of N,N2 -bis(4,6-disubstituted 1,3,5-triazin-2-yl)-4-aminophenethylamine derivatives exemplified by compound 2. This route is a sixstep procedure starting from commercially available cyan

Synthesis of novel rigid triazine-based calix[6]arenes

In this report, the stepwise synthesis of a novel rigid and functionalised macrocycle 2 based on triazine and phenylenediamine linkers, is presented. Poor recognition of the macrocycle 2 for its substrates is observed, which shows experimentally that for the meltriazine based-calix[6]arene system, the binding ability of the melamine moiety gets more benefit from the ring flexibility derived from a xylenediamine linker 1 than from a phenylenediamine linker 2.